Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patient-reported outcomes from dreamm-7 and dreamm-8 using the EQ-5D-3L, patient global impression of severity, and patient global impression of change

View Full Paper
Ask AI
Bookmark
Share

Authors

MPMolly Purser

Discussion

Loading...

Member takes

Overview

Observational study on quality of life and symptom improvement in relapsed multiple myeloma, suggesting benefits of belantamab mafodotin combinations.

Key Points

  • To evaluate patient-reported outcomes from DREAMM-7 and DREAMM-8 trials using various assessment tools.
  • Assessed patient-reported outcomes using EQ-5D-3L VAS, PGIS, and PGIC instruments.
  • Evaluated symptom severity and quality of life in patients with relapsed multiple myeloma.
  • Utilized descriptive statistics and Cox model for time-to-event endpoints.
  • Overall quality of life remained similar between treatment arms in DREAMM-7 and DREAMM-8.
  • Median time to first deterioration in VAS score was 9.5 months for BVd and 13.7 months for DVd in DREAMM-7.
  • Patient-reported symptom severity showed consistent improvements in BVd and BPd arms compared to DVd and PVd.

Cite This Study

Molly Purser (2025) studied this question.

synapsesocial.com/papers/693624dd4fa91c937236d17fhttps://doi.org/10.1182/blood-2025-5823
View Full Paper
Ask AI
Bookmark
Share